Corcept Therapeutics Investigated for Securities Law Violations

jueves, 5 de febrero de 2026, 4:57 am ET1 min de lectura
AGL--
CORT--

The DJS Law Group is investigating claims on behalf of Corcept Therapeutics Incorporated investors for securities violations. The investigation focuses on whether the company issued misleading statements and/or failed to disclose information pertinent to investors. Corcept received a Complete Response Letter from the FDA regarding its New Drug Application for relacorilant, which did not meet the FDA's benefit-risk assessment for hypertension treatment.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios